Introduction
Atherosclerotic cardiovascular complications are major causes of morbidity and mortality. The precise mechanism underlying the development of atherosclerotic vascular disease has not been fully elucidated [1, 2] .
Adiponectin is a protein hormone secreted exclusively by adipocytes. It is a member of the adiposecreted proteins termed 'adipocytokines' or 'adipokines' [2] [3] [4] . Adiponectin has been proposed to exhibit a protective effect against atherosclerosis. It is involved in glucose and lipid metabolism [2] [3] [4] [5] [6] . It has been found that hypoadiponectinemia is associated with obesity, type 2 diabetes, insulin resistance, hyperinsulinemia, and dyslipidemia [4] [5] [6] . Furthermore, hypoadiponectinemia was found to be associated with an increased risk of coronary artery disease (CAD) and may be related to the development of acute coronary syndromes [5, 7] .
Leptin, the product of the obese gene, is mainly produced by adipocytes. Leptin is a satiety factor that regulates body weight by inducing a decrease in the food intake and an increase in the energy consumption. Plasma leptin concentration reflects the amount of adipose tissue and positively correlates with the insulin resistance [8] . Furthermore, leptin is involved in a number of diverse physiological processes, such as regulation of endocrine functions, inflammation, immune response, reproduction, and angiogenesis [9] [10] [11] [12] [13] [14] [15] .
Leptin receptors have been also identified in various peripheral tissues, including in the cardiovascular system and in human coronary arteries. It seems to have both vasodilatory and vasoconstrictory actions on vascular endothelium. The exact role of leptin in cardiac and vascular homeostasis is still not completely understood [12, 13] .
This study aims to determine the relationship between both serum adiponectin and leptin levels and the presence and degree of coronary atherosclerosis.
Methods

Patients
Seventy consecutive patients performing diagnostic cardiac catheterization in the Assiut University Hospital Catheterization Laboratory for the investigation of CAD were recruited. Patients were excluded if they had peroxisome proliferator-activated receptor-a or g agonists, concurrent inflammatory or neoplastic disease, hemodynamically significant valvular heart disease, or earlier revascularization procedure. The control group included 20 patients who were nondiabetics, nonhypertensives, with no history of a previous acute coronary syndrome, having normal electrocardiography, of matched age, sex, body mass index, and waist/hip ratio (WHR), performing coronary angiography for stable angina with inadequate exercise test results and proved to have a completely normal coronary angiography. The study was approved by the 'Assiut Faculty of Medicine' ethics committee. It was fully funded by 'Assiut Faculty of Medicine Research Grants Office'. All patients and controls gave an informed consent to the study protocol. All cases and controls were subjected to complete history and clinical examination including 12-lead electrocardiography, measurement of body mass index, and WHR.
Laboratory measurements
Fasting blood samples were obtained before angiography. Serum was separated immediately by centrifugation and kept at -201C until analysis. Serum adiponectin concentration was assayed with an adiponectin ELISA kit (Biovendor Laboratory Medicine, Inc., Czech Republic). Serum leptin was assayed with human leptin ELISA kit (DRG international, Inc., Germany). Total cholesterol, triglyceride, high-density lipoprotein (HDL)-cholesterol, and glucose levels were measured by enzymatic colorimetric method using reagents from Human Gesellschaft fur Biochemica Diagnostica mbH, Germany. Low-density lipoprotein (LDL)-cholesterol was calculated by Friedewald's formula [16] .
Evaluation of coronary atherosclerosis by angiogram
Angiographic evaluation of coronary atherosclerosis was carried out by assessing three atherosclerotic indices; severity, extent using the criteria of Bogaty et al. [17] , and pattern of the lesion as described below.
Severity pertains exclusively to the degree of narrowing (transverse disease), and was evaluated by counting the number of major epicardial vessels with more than or equal to 70% narrowing of the lumen diameter. The maximum number of vessels was three. Left main stenosis of more than or equal to 50% was counted as two vessels.
Extent considers the proportion of each coronary segment that appears abnormal (longitudinal disease). The coronary arteries were classified into 15 segments; one is the left main, five in the left anterior descending (proximal, mid, distal, and two diagonals), four in the nondominant left circumflex (proximal, distal, and two obtuse marginals), and five in the dominant right coronary (proximal, mid and distal, posterior descending, and posterior left ventricular arteries). For each of these segment, a score ranged from 0 to 3 was given as according to the length of the abnormal segment (narrowed and/or irregular) as follows; 0 if angiographically normal, 1 if abnormal (r 10%), 2 if abnormal (> 10-50%), and 3 if abnormal (> 50%). Then, the extent index was calculated by dividing the extent score calculated from the segments seen by antegrade flow divided by their number; thus it could range from 0 (score of 0) to a maximum of 3 (score of 45 divided by 15).
Pattern describes the complexity of the atherosclerotic lesion. A pattern score was obtained from each of the 15 segments above ranging from 0 to 3 according to the lesion complexity described in the American College of Cardiology/American Heart Association classification [18] as follows; 0 if normal, 1 if type A lesion, 2 if type B lesion, and 3 if type C lesion. Then, the pattern index was calculated in the same way as the extent index by dividing the pattern score calculated from the segments seen by antegrade flow divided by their number.
Statistical analysis
All data were analyzed using SPSS (Statistical Program for Social Sciences, version 14 for windows, 2006, SPSS Inc., Chicago, Illinois, USA). Continuous variables were expressed as mean ± standard deviation and discrete variables were presented as frequencies and percentages. Continuous variables were compared between the two groups using the unpaired Student's t-test for normally distributed data and the Mann-Whitney U test for nonnormally distributed data. Discrete variables were compared using the w 2 test. For each of the atherosclerosis indices, the univariate predictors were determined by Pearson correlation for the continuous variables and Spearman correlation for discrete variables. For each of the indices, the significant univariate predictors were entered in a stepwise multivariate regression model to determine the independent predictors. Statistical significance was defined as a P value of less than 0.05.
Results
The clinical and laboratory characteristics of the study groups are shown in Table 1 . The patients group included 22 diabetics (31%), 42 hypertensive patients (60%), 36 patients (51%) with previous unstable angina, and 34 patients (49%) with a previous myocardial infarction (MI). Compared with the control group; the patient group had significantly lower adiponectin, and HDLcholesterol levels and higher leptin, fasting blood glucose, total cholesterol, and LDL-cholesterol levels.
The predictors of the severity, extent, and pattern indexes of coronary atherosclerosis are shown in Tables 2-4, respectively. The independent predictor of the atherosclerosis lesion severity was larger WHR (b, 0.34), For the extent of atherosclerosis index, lower serum adiponectin level was by far the most important independent predictor (b, -0.45), followed by higher LDL-cholesterol (b, 0.23), older age, and previous MI (b, 0.21 for both), whereas higher serum leptin level was only a univariate predictor. The model-adjusted r 2 was 65%.
For the atherosclerosis pattern index, which represents the lesion complexity, the independent predictors were previous MI (b, 0.31), lower serum adiponectin level (b, -0.29), larger WHR (b, 0.26), higher serum leptin level (b, 0.24), older age (b, 0.22), and higher fasting blood glucose level (b, 20) . The model-adjusted r 2 was 62%.
Discussion
The adipose tissue is not only an organ of energy storage but also a secretory organ producing a variety of bioactive substances, including adiponectin, leptin, tumor necrosis factor-a (TNF-a), and plasminogen activator inhibitor type 1 that may contribute directly to the development of vascular disease [3] .
This study confirms the previous reports that plasma adiponectin levels are lower in patients with coronary atherosclerosis [4, 5, 19] and that it is an independent predictor of both extent and severity of CAD [7, 19] . However, Lim et al. [20] found no significant relation between serum adiponectin and the extent or severity of coronary atherosclerosis. This controversy can be in part explained by the differences in the methods of assessment of the atherosclerosis indices. We also found that adiponectin independently predicted the atherosclerosis pattern index. To our knowledge, this relationship has not been assessed in previous reports.
Studies in experimental animals have shown that adiponectin has the potential to inhibit neointimal formation [6] . Kubota et al. [6] reported that adiponectin-deficient mice have severe neointimal thickening and increased proliferation of vascular smooth muscle cells in mechanically injured arteries. Moreover, neointimal proliferation is attenuated by adenovirus-mediated adiponectin administration in mice [1] .
One of the initial steps in atherogenesis is adherence of monocytes to endothelial cells and their migration into the subendothelial space, where they take up oxidized lipoproteins and transform into foam cells. Plasma adiponectin rapidly accumulates in the subendothelial space of the injured human artery [1] . In physiological concentration, adiponectin has a dose-dependent inhibitory effect of TNF-a-mediated expression of vascular cell-adhesion molecules-1, endothelial leukocyte-adhesion molecule, and intracellular-adhesion molecule-1, thus it inhibits monocyte adhesion to endothelial cells and foam cell formation [3] . Adiponectin suppresses lipid accumulation in macrophages, resulting in markedly decreased uptake of oxidized LDL and inhibition of foam cell formation [2] . Adiponectin also binds to platelet-derived growth factor-BB and subendothelial collagens and suppresses proliferation and migration of vascular smooth muscle cell, therefore limiting the progression of atherosclerosis and re-stenosis [3] . Moreover, adiponectin exerts its vascular actions by direct stimulation of nitric oxide production in endothelial cells and taking part in vasodilator actions and increasing blood flow [21] .
In this study, serum leptin levels were higher in patients with coronary atherosclerosis than controls. Serum leptin was correlated positively with the severity, extent, and pattern of coronary atherosclerosis. However, on multivariate analysis, the high level of serum leptin was an independent factor affecting the severity and pattern only, but not the extent of coronary atherosclerosis. Leptin was previously reported to be an independent predictor of CAD [22, 23] . However, other investigators emphasized a potential protective role of leptin in CAD [24] [25] [26] .
Functional leptin receptors are present on endothelial cells. However, the actions of leptin to modulate endothelial function remain controversial. Leptin can elicit changes that may be detrimental to cardiovascular health. It may stimulate increases in oxidative stress, which may interact with nitric oxide to form peroxynitrite and, thereby, decreases the bioavailability of nitric oxide, which is associated with an impairment of endotheliumdependent vasodilation [27] . Leptin also promotes neointimal growth in mice [27] and stimulates migration and proliferation of vascular smooth muscle cells [28] . Leptin stimulates synthesis and secretion of endothelin-1, a potent vasoconstrictor and mitogen [29] . It potentiates the production of inflammatory cytokines, for example, TNF-a and interleukins 2 and 6 in cells [9] . Leptin stimulates lipoprotein lipase secretion in macrophages and increases accumulation of cholesterol esters in foam cells, especially at high glucose concentrations [10] . Leptin promotes hepatic HDL and decreases plasma HDL level in mice [11] .
In contrast, there is evidence supporting several potentially beneficial effects of leptin. Momin et al. [12] reported that leptin is an endothelium-independent vasodilator in saphenous vein and internal mammary artery vascular rings isolated from patients with CAD. These vascular effects in an isolated preparation are independent of any neurally mediated actions of leptin. They are consistent with several previous reports showing leptin-induced coronary artery vasodilation in humans and activation of endothelial nitric oxide production in human aortic endothelial cells [13] . Leptin may also activate adult human endothelial progenitor cells and promotes angiogenesis [14] . Under normoglycemic conditions, leptin may protect macrophages from cholesterol overload [15] .
This apparent discrepancy between the potentially protective actions of leptin, and its association with an impaired cardiovascular outcome in epidemiological studies, may be reconciled by several explanations, including: first, the broad spectrum of cardiovascular actions of leptin; second, dosedependent effects of leptin; and third, the concept of selective leptin resistance [30] .
Conclusion
Both serum adiponectin and leptin might play an important pathogenic role not only in the occurrence but also in the severity, extent, and lesion complexity in patients with CAD. WHR, probably reflecting visceral obesity, is an important predictor of the degree of coronary atherosclerosis.
